证券代码：688029 证券简称：南微医学 公告编号：2025-036 南微医学科技股份有限公司 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 截至本公告日，深圳市中科招商创业投资有限公司（以下简称"中科招商"） 持有南微医学科技股份有限公司（以下简称"公司"）股份 41,752,818 股，占公司 总股本的 22.2270%。上述股份来源为公司首次公开发行股票并上市前取得的股 份，及该等股份于公司 2022 年实施资本公积转增股本时获得股份，上述股份已 于 2022 年 7 月 22 日起上市流通。 减持计划的主要内容 预披露期间，若公司股票发生停牌情形的，实际开始减持的时间根据停牌时间相应顺延 （一）相关股东是否有其他安排 □是 √否 公司股东中科招商因自身资金需求，拟通过上海证券交易所交易系统以集中 竞价、大宗交易方式减持公司股份合计不超过 3,756,948 股，其中拟通过证券交 易所集中竞价交易方式进行减持的，将于减持计划公告 ...

人民财讯8月17日电，南微医学(688029)8月17日晚间公告，持股22.23%的股东中科招商因自身资金需 求，拟以集中竞价、大宗交易方式减持公司股份合计不超过375.69万股，其中拟通过集中竞价交易方式 减持公司股份不超过187.85万股；拟通过大宗交易方式减持公司股份不超过187.85万股。本次拟通过以 上两种方式减持的股份合计不超过公司总股本比例的2%。 ...

南微医学(688029.SH)公告，公司股东中科招商拟以集中竞价、大宗交易方式减持公司股份合计不超过 375.69万股，计划减持比例不超过2%。 ...

智通财经APP讯，南微医学(688029.SH)公告，公司股东中科招商拟以集中竞价、大宗交易方式减持公 司股份合计不超过375.69万股，计划减持比例不超过2%。 ...

- The report tracks quantitative sentiment indicators, including volume timing signals, which show optimistic views for major broad-based indices except for the Beixin 50 index, which is cautious[24][25] - The "HS300 Upward Stock Count Ratio" sentiment indicator is calculated as the proportion of HS300 constituent stocks with positive returns over the past N days. This indicator captures market sentiment and is effective in identifying upward opportunities but has limitations in predicting downward risks[25][26] - The "Momentum Sentiment Indicator" uses two smoothed lines (short-term and long-term) to track sentiment changes. When the short-term line exceeds the long-term line, it signals optimism in the market. Parameters include N=230, N1=50, and N2=35[28][29][32] - The "Moving Average Sentiment Indicator" evaluates the HS300 index's trend using eight moving averages (8, 13, 21, 34, 55, 89, 144, 233). When the closing price exceeds the values of more than five moving averages, it signals optimism[32][33][35] - Cross-sectional volatility analysis shows that the Alpha environment has improved in the short term for HS300, CSI500, and CSI1000 indices. However, over the past quarter, the Alpha environment remains average to poor based on historical volatility levels[37][41] - Time-series volatility analysis indicates an improvement in Alpha environment in the short term for HS300, CSI500, and CSI1000 indices. However, over the past quarter, the Alpha environment remains below average based on historical volatility levels[37][42]

Group 1 - The core viewpoint of the articles highlights a positive trend in the medical device sector, with major stocks experiencing significant gains, indicating a recovery in the market [1] - The medical device index ETF (159898) showed a morning rebound with a rise of 1.03%, attracting over 15 million yuan in net subscriptions, reflecting investor confidence [2] - Future growth in the medical device industry is expected to be driven by technological advancements, AI diagnostics, and the expansion of consumer healthcare, transitioning to a higher development stage [2] Group 2 - Financial institutions like Caixin Securities maintain a "leading the market" rating for the medical device sector, anticipating high-quality development and long-term investment opportunities [2] - The impact of centralized procurement in high-cost areas is gradually diminishing, with some products benefiting from renewed contracts, suggesting a potential for volume and price increases in the coming years [2] - The medical device index ETF (159898) has seen a cumulative net value increase of 22.82% over the past year, outperforming its benchmark by 5.99%, ranking first among similar index ETFs [2][3]

Core Insights - The medical device sector has shown significant activity since June 23, with the medical device ETF (562600) recording 25 out of 39 trading days with gains [1] - Recent policy optimizations, including the launch of the 11th batch of centralized procurement and the announcement from the National Healthcare Security Administration to alleviate price competition, are expected to benefit the industry [1] - A joint initiative from seven departments aims to promote innovation in the brain-computer interface industry, targeting key technological breakthroughs by 2027 and establishing a reliable industrial system by 2030 [1] Industry Overview - The medical device ETF (562600) serves as a convenient tool for investors to capture growth opportunities in the medical device sector, tracking the CSI All Share Medical Device Index [1] - The index comprises 100 representative listed companies across core medical fields, including medical devices, medical services, and medical information technology, with a high concentration in the medical device industry at 89.34% and brain-computer interface content at 21.9% [1] - The industry structure indicates a strong concentration, allowing for precise capture of development dividends in the medical device field [1]

Group 1 - The core viewpoint of the article highlights the movements of social security funds in the stock market, particularly their investments in eight stocks on the Sci-Tech Innovation Board, with a total holding of 30.19 million shares valued at 1.364 billion yuan [1] - Social security funds increased their holdings in five stocks, entered one new stock, and reduced their holdings in one stock, while one stock's holding remained unchanged [1] - The stocks with the highest holdings by social security funds include Nanwei Medical and Kaili New Materials, with holdings of 9.1785 million shares and 6.3642 million shares, respectively [1][3] Group 2 - In terms of performance, eight stocks held by social security funds reported year-on-year net profit growth in the first half of the year, with the highest growth seen in Rongzhi Rixin at 14.2355 million yuan, reflecting a staggering increase of 2063.42% [2] - The social security funds' holdings are primarily concentrated in the pharmaceutical and basic chemical industries, with two stocks from each sector appearing on the list [3] - Since July, the average increase in the stocks held by social security funds on the Sci-Tech Innovation Board has been 25.90%, with Dingtong Technology showing the highest cumulative increase of 75.47% [3]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Nanwei Medical, which has a current stock price of 94.95 yuan and a rolling PE ratio of 29.43 times, significantly lower than the industry average of 55.76 times [1][2] - As of June 30, 2025, the number of shareholders in Nanwei Medical decreased to 12,345, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, manufacturing, and sales of minimally invasive medical devices, with key products including endoscopic diagnostic instruments and microwave/radiofrequency ablation equipment [1] Group 2 - In the latest half-year report for 2025, Nanwei Medical achieved a revenue of 1.565 billion yuan, representing a year-on-year growth of 17.36%, and a net profit of 363 million yuan, also reflecting a year-on-year increase of 17.04% [1] - The gross profit margin for the company stands at 64.89%, indicating a strong profitability relative to its revenue [1] - The industry average PE ratio is 55.76, while the median is 39.14, positioning Nanwei Medical at the 58th rank within the medical device sector [2]

Investment Rating - The investment rating for Nanwei Medical (688029) is not explicitly stated in the provided documents, but the report indicates a positive outlook based on growth metrics and market performance [1][3]. Core Viewpoints - The company reported a revenue of 1.565 billion yuan in the first half of 2025, representing a year-over-year increase of 17.36%, with a net profit of 363 million yuan, also up by 17.04% [1][3]. - The overseas market showed significant growth, with revenue reaching 899 million yuan, a year-over-year increase of 43.81%, highlighting the company's successful global expansion strategy [3]. - The company is focusing on innovation, with a research and development expense ratio of 5.64%, which is expected to enhance its competitive position in the market [3]. Summary by Sections Financial Performance - In the first half of 2025, the company achieved an operating income of 1.565 billion yuan, with a net profit of 363 million yuan and an operating cash flow of 302 million yuan [1][3]. - For Q2 2025, the revenue was 866 million yuan, reflecting a year-over-year growth of 21.36% [1]. Market Segmentation - Domestic revenue was 656 million yuan, down 7.10% year-over-year, while overseas revenue was 898 million yuan, up 43.81% year-over-year, indicating a shift towards international markets [3]. - The Americas contributed 341 million yuan, a 21.75% increase, while Europe, the Middle East, and Africa saw a remarkable 89% growth, with revenue of 416 million yuan [3]. Product Performance - The endoscope diagnostic instruments generated 1.218 billion yuan in revenue, growing 8.02% year-over-year, with core growth drivers identified as hemostatic closure and EMR/ESD products [3]. - The tumor intervention business achieved revenue of 114 million yuan, reflecting a 2.53% increase, supported by product optimization efforts [3]. Future Projections - Revenue forecasts for 2025-2027 are 3.286 billion yuan, 3.915 billion yuan, and 4.635 billion yuan, with year-over-year growth rates of 19.3%, 19.1%, and 18.4% respectively [4]. - Net profit projections for the same period are 669 million yuan, 795 million yuan, and 939 million yuan, with growth rates of 21.0%, 18.8%, and 18.1% respectively [4].